Abstract
Background and Aims: High levels of low-density lipoprotein cholesterol (LDL-C) and the overproduction of reactive oxygen species (ROS) underlie the vascular dysfunction and the consequent development of cardiovascular diseases (CVD). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has opened a new era for lipid-lowering therapy and CVD prevention. However, the direct effects of these drugs on vascular functions such as ROS production and arterial stiffness have not been extensively described yet.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.